Raymond James lowered the firm’s price target on Haemonetics (HAE) to $105 from $115 and keeps a Strong Buy rating on the shares. The Q4 print was in line on revenues and slightly ahead on EPS due to below-the-line dynamics, the analyst tells investors in a research note. The guidance for fiscal 2026 is in line to better than hopes even net of a tariff headwind and could still prove conservative, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics Reports Mixed Fiscal 2025 Results
- Haemonetics participates in a conference call with JPMorgan
- Haemonetics: Buy Rating Affirmed Amid Strong Q4 Performance and Margin Improvements
- Haemonetics Approves Strategic Alignment Initiative in May 2025
- Haemonetics sees FY26 adjusted EPS $4.70-$5.00, consensus $4.93
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue